Acne vulgaris
Conditions
Interventions
Group of mild acne:Low-dose isotretinoin <0.5 mg/kg/day
Group of moderate acne:Low-dose isotretinoin <0.5 mg/kg/day
Group of severe acne:Low-dose isotretinoin <0.5 mg/kg/day
Group A:Target cumulative dose 60 mg/kg
Group B:Target cumulative dose 90 mg/kg
Group C:Target cumulative dose 120 mg/kg
Sponsors
the First Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1) Age 18–50 years, male or female; (2) Meets the diagnostic criteria for acne vulgaris and the indications for isotretinoin in the Chinese Guidelines for the Treatment of Acne (2019 Revised Edition); (3) Voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Individuals with immunodeficiency, severe systemic or organic diseases (such as heart, liver, kidney), or malignant tumors; (2) Pregnant or lactating women, or women of childbearing age who have not used effective contraception within the past month and intend to conceive within the next two years; (3) Individuals with mental symptoms, such as depression or anxiety; (4) Obese individuals (BMI >= 28 kg/m^²), those with dyslipidemia, or those with liver disease; (5) Individuals with autoimmune diseases, polycystic ovary syndrome, severe endocrine disorders, or chronic infections; (6) Individuals with severe fulminant acne or special types of acne requiring emergency intervention; (7) Individuals allergic to isotretinoin; (8) Other circumstances deemed unsuitable for participation in this trial by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acne lesion counting;Investigator Global Assessment;Global Acne Grading System;Dermatology Life Quality Index and satisfaction with drug treatment; | — |
Countries
China
Contacts
Public ContactLi Zhang
Department of Dermatology, The First Hospital of China Medical University, Shenyang, China
Outcome results
None listed